Drug Profile

Abexinostat - Xynomic Pharmaceuticals

Alternative Names: Abexinostat hydrochloride; CG-781; CRA-024781; CRA-024781 HCl; CRA-024781-01; PCI-24781; PCI-24781-01; S 78454; S78454-1

Latest Information Update: 08 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Celera Genomics Group
Developer GSK; Janssen Inc; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Pharmacyclics; Servier; University of California at San Francisco; Xynomic Pharmaceuticals
Class Amides; Antineoplastics; Benzofurans; Dimethylamines; Hydroxamic acids; Phenyl ethers; Small molecules
Mechanism of Action Histone deacetylase inhibitors; Rad51 recombinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Phase III Renal cell carcinoma
Phase II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma
Phase I/II Non-Hodgkin's lymphoma; Sarcoma
Phase I Glioma
No development reported Breast cancer; Myelodysplastic syndromes; Nasopharyngeal cancer; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

22 Apr 2025 Xynomic Pharmaceuticals completes a phase I/II trial in Diffuse large B-cell lymphoma and Mantle-cell lymphoma (Second-line therapy or greater, Combination therapy) in USA (PO) (NCT03939182)
31 Dec 2024 GSK completes a phase-I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (NCT01543763),
31 May 2024 Adverse events and efficacy data from a phase II trial in Follicular lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com